Ginkgo Bioworks Holdings, Inc.
DNAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ginkgo Bioworks Holdings, Inc. focuses on Biotechnology services and products. Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. Valued at $516.7M, DNA is a small-cap name in its sector. It operates through the Cell Engineering and Biosecurity segments.
Market Cap
$516.7M
Beta
1.78
P/E (TTM)
—
P/E (Fwd)
-2.46
EPS (TTM)
$-5.13
EPS (Fwd)
$-3.21
ROE
-56.0%
ROA
-16.2%
Cash
$373.5M
Total Debt
$410.7M
Free CF
-$77.9M
52W Change
-21.9%
Annual Financials
Cash vs Debt
On the balance sheet, DNA has $373.5M in cash with $410.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$77.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -56.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $477.7M (2022) to $170.2M (2025), a 64% decline worth watching.
Ginkgo Bioworks Holdings, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Ginkgo Bioworks Holdings, Inc. and its sector.